中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2013, Vol. 48 Issue (2) :148-151    DOI:
ҩ�����ٴ� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
���3����������ֲ���߻�����ѪҩŨ�ȼ�������ٴ�����
��Ƽ����������徣���־�죬��ΰ
ɽ���ൺ��ѧҽѧԺ����ҽԺ��ɽ�� �ൺ 266003
LENG Ping�� CAO Yu�� ZHAO Zheng-huan�� CAO Zhi-hong�� SUN Wei

Download: PDF (0KB)   HTML (1KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ Ŀ�� �Դ��3����������ֲ���߻����أ�CsA��ѪҩŨ�ȼ��Ľ������ͳ�Ʒ��������������߻�������ҩ������ѪҩŨ�ȵĸ�����죬���Ա�����Ĺ�ϵ���������������Ʒ����Ƿ�ɽ��ͻ�����������ѪҩŨ�ȣ�����������ʱ������2����0�Ĺ�ϵ�� ���� ����ӫ��ƫ�����߷���FPIA���ⶨ97������ֲ����1 780���λ�����ѪҩŨ�ȣ���������ʱ�䡢�Ա𡢻������䡢�������Ʒ����������뻷����ѪҩŨ�ȵĹ�ϵ����� ���߽�������ֲ���󣬻�������ҩ������ѪҩŨ��������ʱ����ӳ����𽥽��ͣ��Ҹ������ϴ����������ڣ�Ů�Ի��ߵ���ҩ�����Դ������ԡ���������ʱ����ӳ���Ů�Ի��ߵ���ҩ�����Ե������Ի��ߣ��������������Բ��졣����ҩ�������Ƶ�����£�Ů�Ի��߻�����ѪҩŨ�ȵ������Ի��ߣ�����������24�����Ժ���Ů����ѪҩŨ����Ⱦ��������Բ��죨P<0.05�������������������2�黼�ߵ���ҩ������ѪҩŨ�ȳ��½����ƣ�������ͬһʱ����ڣ�50�����ϻ��߻�������ҩ������ѪҩŨ�ȵ���50�����»��ߣ�������ͳ��ѧ���壨P<0.05���������������Ʒ�������ȣ����������Ʒ������л������������Լ��٣�ѪҩŨ��ֵ���ͣ�������ͳ��ѧ���壨P<0.05����������2����0������ֲʱ���ӳ��������������ļ��ٶ��½������� ����ֲ�����ߵĻ�������ҩ������ѪҩŨ���нϴ�ĸ�����졣Ӧ��ϻ��ߵ��ٴ��������ý���ȫ���������ʱ�������Ʒ�����ʵ�ָ��Ի���ҩ��ʹ������������ֲ���Ӧ�õõ��������Ч����
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
��Ƽ
����
�����
��־��
��ΰ
�ؼ����� ����ֲ   ������   ѪҩŨ�ȼ��     
Abstract�� OBJECTIVE To analyze the results of blood concentration monitoring for cyclosporin A (CsA) in renal transplant recipients who have survived for more than three years�� thus to investigate the relationship between CsA dose�� blood concentration inter-individual variability and gender and age�� and to determine the possibility of decrease CsA dose and blood concentration by new triple therapeutic protocol�� and to analyses the relationship between postoperation time and ��2 and ��0. METHODS The blood concentrations of CsA of 97 patients (1 780 cases) were determined by FPIA method. The relationships between time after surgery�� gender�� age�� immunosuppressive strategy and blood concentration of CsA were analyzed. RESULTS The blood concentration and dose of CsA decreased with time after surgery�� with significant inter-individual difference. The doses for female patients were larger than those for males in the early days after surgery�� and then became smaller than male in later time�� with no statistical significant difference. Under similar doses�� the blood concentrations of CsA in females were lower than those in males�� but with no significant difference. Twenty-four months after transplantation�� significant difference of blood concentration was revealed between female and male patients��P<0.05��. With increasing age�� the dose and blood concentration decreased in the two groups. The dose and blood concentration of CsA in patients elder than fifty years were lower than those in patients younger than fifty years in the same period after surgery. Compared with the old triple therapeutic protocol group�� the dose of CsA and blood concentration decreased in the new triple therapeutic protocol group with significant difference. The ��2 and ��0 decreased following the time after operation with reduction of CsA dose. CONCLUSION Significant individual difference exists in the dose and blood concentration of CsA in patients after renal transplantation. Multianalysis of the clinical feature of patients should be performed to adjust the therapeutic protocols�� thus to achieve personalized pharmacotherapy and the best treatment results.
Keywords��   
�ո�����: 2012-01-01;
���߼��: ��Ƽ��Ů��˶ʿ������ҩʦ �о������ٴ�ҩѧ ��ͨѶ���ߣ���ΰ��Ů������ҩʦ��˶ʿ����ʦ �о������ٴ�ҩѧ Tel��(0532)82911599 E-mail��sunwei@medmail.com.cn
���ñ���:   
��Ƽ, ����, ����徵� .���3����������ֲ���߻�����ѪҩŨ�ȼ�������ٴ�����[J]  �й�ҩѧ��־, 2013,V48(2): 148-151
LENG Ping, CAO Yu, ZHAO Zhen-Huan etc .Analysis of Blood Concentration Monitoring Result for Cyclosporin A in Renal Transplant Recipients Surviving for more than Three Years[J]  Chinese Pharmaceutical Journal, 2013,V48(2): 148-151
��
[1] FANG W��ZHANG Q Y��QIAN J Q��et al.Application of Tc-DTPA clearence compared with the traditional method in the measurement of glomerular filtration rate. Chin J Nephrol (�л����ಡ��־)��1998��14(3)��177-180.
[2] POTTER J M. Pharmacoeconomics of therapeutic drug monitoring in transplantation.Ther Drug Monit�� 2000��22(1)��36-39.
[3] ZHAI S D��YING Y Q. Drug Prescribing in Renal Failure(��˥ҩ���ֲ�). 1th ed. Beijing��People's Medical Publishing House�� 2010��726. Drug Prescribing in Renal Failure(��??��?�㨨?��?????????). 1th ed. Beijing???People --- unreasonable DOI found: doi=YING Y Q. Drug Prescribing in Renal Failure(��??��?�㨨?��?????????). 1th ed. Beijing???People target="_blank">
[4] JAY P. Sanford. The Sanford Guide to Antimicrobial Therapy(�Ȳ�). 40th ed. Beijing�� Peking Union Medical College Press��2011��186.
[5] CHARLES F L�� LORA L A�� MORTON P G�� et al. Drug Information Handbook. 12th ed. Hudson�� Lexi-Comp Inc�� 2004��1653.
[6] COCKCROFT D W�� GAULT M H. Prediction of creatinine clearance from serum creatinine. Nephron��1976�� 16(1)��31-41.
[7] BOWERS L D. Therapeutic monitoring for cyclosporine�� Difficulties in establishing a therapeutic window.Clin Biochem ��1991��24(1)��81-87.
[8] SOKOLL L J�� RUSSELL R M�� SADOWSKI J A�� et al. Establishment of creatinine clearance reference values for older women. Clin Chem�� 1994�� 40(11) ��2276-2281.
[9] MIN Z L�� ZHU Y H. A study of renal transplant recipients survived of more than 10 years. Chin J Organ Transplant(�л�������ֲ��־)�� 1995��16(3)��100-102.
[10] National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease�� Evaluation�� classification�� and strati-fication. Am J Kidney Dis�� 2002�� 39(suppl 1)��261-266.
[11] YU A R�� WU X C�� LI X�� et al. Gender difference of pharmacokinetics of oral cyclosporine A in renal transplanted recipients. Chin J Clin Pharmacol Ther(�й��ٴ�ҩ��ѧ������ѧ)�� 2004��9(2)��220-222.
[12] HULL J H�� HAK L J�� KOCH G G�� et al. Influence of range of renal function and liver disease on predictability of creatinine clearance. Clin Pharmacol Ther�� 1981�� 29(4)��516-521.
[13] KOUP J R�� ABEL R B�� SMITHERS J A�� et al. Effect of age�� gender and race on steady state procainamide pharmacokinetics after administration of procanbid sustained-release tablets. Ther Drug Monit��1998��20(1)��73-77.
[14] ZHOU H L�� LI L H�� WANG J G�� et al. Clinical value of supervising rational application of CsA by monitoring CsA concentration C2 and C0 in kidney transplant recipients.J Jilin Univ(Med Edit)(���ִ�ѧѧ��ҽѧ��)��2007��33(4)��757-758.
[15] LAM N P�� SPERELAKIS R�� KUK J��et al. Rapid estimation of creatinine clearances in patients with liver dysfunction. Dig Dis Sci�� 1999�� 44(6)��1222-1227.
[16] CHEN L Y�� SHI D H�� CENG S Q�� et al. A sensitive predictor of renal allograft rejection �� Two-hour post-dose blood concentration of cyclosporine A.Chin Pharm J (�й�ҩѧ��־)��2004��39(9)��707-708.
[1] ��������Ԭ�飬��Ц�ԣ���־��.�������Ƽ�������ֲ�����е�Ⱥ��ҩ��ѧ�о���չ[J]. �й�ҩѧ��־, 2013,48(1): 9-12
[2] Ф���� ���� ��� ƽ���� ��־�� .������A��������֬��������Ʊ�������[J]. �й�ҩѧ��־, 2012,47(5): 362-366
[3] κ���壬ʯ����������������֣����������.������ֲ��������AѪҩŨ�ȼ�����ٴ���Ч��ϵ���о�[J]. �й�ҩѧ��־, 2012,47(18): 1503-1508
[4] Ф�����������࣬ƽ���ܣ���־��.������A����𤸽������֬��������Ʊ����ڼ����۲���֯�ֲ��о�[J]. �й�ҩѧ��־, 2012,47(15): 1227-1232
[5] ����ͬ �Ż� ����Ƽ �ۺ� ����� �ﴺ��.ABCB1��CYP3A5�����̬�ԶԻ�����ѪҩŨ�ȵ�Ӱ��[J]. �й�ҩѧ��־, 2011,46(5): 368-373
[6] л�� �κ��� ���컪 ��˳�� ̷����.CYP3A5*3��MDR1 G2677T/A�����̬�Զ�����ֲ���߻�����AѪҩŨ�ȼ���Ч��Ӱ��[J]. �й�ҩѧ��־, 2011,46(20): 1591-1596
[7] ������ ���� ���� ���� ����÷ ������ ���� ������.���ӱ����Ƽ�������ֲ��������ù������ѪҩŨ�ȵ�Ӱ��[J]. �й�ҩѧ��־, 2011,46(16): 1273-1275
[8] ����÷ ���� ���� ���� ������.ARCHITECT��TDx�ⶨ������AѪҩŨ��������о�[J]. �й�ҩѧ��־, 2011,46(13): 1020-1022
[9] ��С�� ��ǿ ����.�����ۺ������ߵĻ�����AѪҩŨ��Ӱ�����ط���[J]. �й�ҩѧ��־, 2010,45(9): 686-689
[10] �ƻ��� ������ ����.MDR1G2677T/A�����̬�ԶԻ�����ҩ���л����ѧ��ҩЧѧӰ���ϵͳ����[J]. �й�ҩѧ��־, 2010,45(2): 140-143
[11] ���� ���� ���� ����÷ ���� ������.����ֲ����IFN-�� mRNA����������������Ƽ�ҩЧ���������[J]. �й�ҩѧ��־, 2010,45(17): 1343-1347
[12] �࿡�� ʷ���� ������ ��ɺ �Ľ� ���� �°�Ƽ ������.�����˹�������Ļ�����A���廯��ҩ���[J]. �й�ҩѧ��־, 2010,45(12): 927-930
[13] �˳��� �Ź��� ���� �е�Ϊ ������ ¬� .�й�����ֲ��������Ī˾����ҩ�������������[J]. �й�ҩѧ��־, 2010,45(10): 775-779
[14] �ﲫ �߾�ΰ ������ �ǽ��� ������ ��־�� ������.�й�����ֲ���߿ڷ������ص��ٴ�������Ⱥ��ҩ��ѧ�о�[J]. �й�ҩѧ��־, 2010,45(1): 46-51
[15] ������ ;���� ;���E ;�ƽ�Ȩ ;��־�� ;�ﴺ�� . HPLC-MS/MS �� FPIA ���ⶨȫѪ�л�����Ũ�ȵıȽϷ���ѧ[J]. �й�ҩѧ��־, 2009,44(24): 1904-1907
Copyright 2010 by �й�ҩѧ��־